ABSTRACT
In a double-blind, between-patient trial, 30 patients affected by acute ocular inflammation were treated with either pirprofen capsules (400 mg twice daily) or indomethacin capsules (50 mg twice daily) for 14 days. Treatment efficacy was evaluated in basal conditions and after 3, 6, 10 and 14 days on the basis of the following criteria: keratic injection, Tyndall phenomenon, vitreous changes, endothelial precipitates and pain severity, all according to 4-point scales. At the end of the study, a final judgement was expressed by the physician. Non-parametric statistical tests showed that both treatments significantly modified all the parameters considered. Both drugs were well tolerated; only 1 patient on pirprofen dropped out because of gastralgia.
Subject(s)
Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Keratitis, Dendritic/drug therapy , Phenylpropionates/therapeutic use , Uveitis, Anterior/drug therapy , Adolescent , Adult , Aged , Clinical Trials as Topic , Double-Blind Method , Female , Humans , Indomethacin/therapeutic use , Male , Middle Aged , Random Allocation , Time FactorsABSTRACT
In a double-blind, between-patient trial, a new cyclo-oxygenase inhibitor, pirprofen (800 mg/day), was compared with indomethacin (100 mg/day) and placebo in 56 patients undergoing cataract extraction. Treatment started 48 h before operation and continued for eight days. Patients were examined on days 1, 3 and 6 for objective signs of inflammation and pain. Both active drugs proved to have good anti-inflammatory action, clearly superior to placebo. No unwanted effects or modifications in laboratory parameters other than those related to the antiphlogistic effect were reported.
